This time may be different

  title={This time may be different},
  author={Bruce L. Booth},
  journal={Nature Biotechnology},
B has been witnessing the greatest five-year bull run in the industry’s history. The optimism for the sector and for new biomedical product innovation has manifested itself across the public and private markets, fundraising metrics, initial public offerings (IPOs) and secondary offerings and partnering activity. A quick review of the summary data underscores that exuberance: as of October 2015, the public markets, as measured by the NASDAQ Biotech Index, were up some 200% relative to the S&P… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.
1 Citations
5 References
Similar Papers


Publications citing this paper.


Publications referenced by this paper.
Showing 1-5 of 5 references

Emerging therapeutic company investment and deal trends (Biotechnology

  • D. Thomas, C. Wessel
  • Industry Organization,
  • 2015

Improving the Pharma Research Pipeline McKinsey Quarterly

  • B Booth
  • Web Exclusive August
  • 2004

Boom time for biotech

  • M. Slud
  • CNNMoney (22 February
  • 2000

Promise to Reality

  • Ernst, Young. Biotech ’92
  • Ernst & Young Annual Biotech Report. 1992
  • 1992

Similar Papers

Loading similar papers…